We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$11.9B
AUM Growth
+$2.55B
(+27%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
28.34%
Holding
1,181
New
44
Increased
774
Reduced
301
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$294M |
| 2 |
Apple
AAPL
|
+$74.6M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$68.1M |
| 4 |
Tesla
TSLA
|
+$64.9M |
| 5 |
Microsoft
MSFT
|
+$51.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$12.3M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$8.37M |
| 3 |
CLR
CONTINENTAL RESOURCES INC.
CLR
|
+$7.53M |
| 4 |
ASML
ASML
|
+$7.05M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$6.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.81% |
| 2 | Financials | 13.96% |
| 3 | Healthcare | 11.37% |
| 4 | Energy | 7.72% |
| 5 | Consumer Discretionary | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Sarepta Therapeutics
SRPT
$1.64B
| $9.15M | 0.08% |
70,634
+9,803
| +16% | +$1.14M |
|
202
Incyte
INCY
$24.9B
| $9.15M | 0.08% |
113,939
+8,146
| +8% | +$623K |
|
203
Vaxcyte
PCVX
$8.08B
| $9.12M | 0.08% |
190,302
+96,889
| +104% | +$3.8M |
|
|
DEN
204
DELISTED
Denbury Inc.
DEN
| $9.09M | 0.08% |
104,462
+15,039
| +17% | +$1.37M |
|
205
HF Sinclair
DINO
$16.7B
| $9.08M | 0.08% |
174,987
+25,680
| +17% | +$1.48M |
|
206
CNX Resources
CNX
$4.9B
| $9.07M | 0.08% |
538,555
+76,812
| +17% | +$1.33M |
|
207
T-Mobile US
TMUS
$186B
| $9.05M | 0.08% |
64,632
-364
| -0.6% | -$52.3K |
|
208
American Tower
AMT
$81.3B
| $9.03M | 0.08% |
42,609
+14,815
| +53% | +$3.08M |
|
209
Murphy Oil
MUR
$5.48B
| $8.95M | 0.07% |
208,089
+8,921
| +4% | +$402K |
|
|
EXAS
210
DELISTED
Exact Sciences
EXAS
| $8.95M | 0.07% |
180,765
+10,281
| +6% | +$420K |
|
211
Arch Capital
ACGL
$34.5B
| $8.94M | 0.07% |
+142,479
| New | +$7.95M |
|
212
Matador Resources
MTDR
$6B
| $8.92M | 0.07% |
155,769
+19,746
| +15% | +$1.25M |
|
213
Rhythm Pharmaceuticals
RYTM
$7.25B
| $8.91M | 0.07% |
306,013
+43,725
| +17% | +$1.12M |
|
214
Chord Energy
CHRD
$7.78B
| $8.9M | 0.07% |
65,019
+7,912
| +14% | +$1.16M |
|
215
TG Therapeutics
TGTX
$8.19B
| $8.89M | 0.07% |
751,779
-21,431
| -3% | -$156K |
|
216
Medtronic
MDT
$110B
| $8.89M | 0.07% |
114,354
+43,268
| +61% | +$3.51M |
|
217
Acadia Pharmaceuticals
ACAD
$4.55B
| $8.86M | 0.07% |
556,681
+158,005
| +40% | +$2.47M |
|
|
CTIC
218
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $8.84M | 0.07% |
1,471,357
+378,314
| +35% | +$2.06M |
|
219
BioCryst Pharmaceuticals
BCRX
$2.35B
| $8.82M | 0.07% |
768,073
+252,845
| +49% | +$3.15M |
|
|
CIVI
220
DELISTED
Civitas Resources
CIVI
| $8.8M | 0.07% |
151,857
+32,996
| +28% | +$2.13M |
|
221
Philip Morris
PM
$299B
| $8.77M | 0.07% |
86,639
+43,082
| +99% | +$4.07M |
|
|
PDCE
222
DELISTED
PDC Energy, Inc.
PDCE
| $8.75M | 0.07% |
137,905
+17,783
| +15% | +$1.24M |
|
|
MRTX
223
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.75M | 0.07% |
193,073
+111,361
| +136% | +$7.21M |
|
224
Insmed
INSM
$22B
| $8.73M | 0.07% |
436,802
+157,722
| +57% | +$3.05M |
|
|
VTLE
225
DELISTED
Vital Energy
VTLE
| $8.71M | 0.07% |
169,454
+62,743
| +59% | +$3.87M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Rafferty Asset Management held 1,181 positions worth $11.9B, up 27% from $9.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q4 2022, opening 44 new positions and adding to 774 existing holdings. Its largest new stake was Akero Therapeutics: 187,799 shares worth $10.3M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 38% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Microchip Technology, an estimated $12.3M trimmed.
- Rafferty Asset Management's largest Q4 2022 buy was Akero Therapeutics: 187,799 shares worth $10.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2022, an estimated $294M increase.
- Rafferty Asset Management's biggest Q4 2022 reduction was Microchip Technology, cutting an estimated $12.3M.
- Rafferty Asset Management fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $7.53M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $11.9B portfolio in Q4 2022.
- Rafferty Asset Management opened 44 new positions and closed 61 in Q4 2022.
- Rafferty Asset Management's portfolio value rose 27% quarter-over-quarter to $11.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.